尽管利强,并且有新的口服糖尿病药物,但Novo Nordisk股价在2026年2月19日下跌1.6%,原因是指导和竞争较弱. Novo Nordisk stock dropped 1.6% on Feb. 19, 2026, despite strong earnings and a new oral diabetes drug, due to weak guidance and competition.

2026年2月19日Novo Nordisk股票下跌1.6%至48.46美元, Novo Nordisk stock fell 1.6% to $48.46 on February 19, 2026, amid lower-than-average trading volume, despite strong Q4 earnings and a new oral GLP-1 drug gaining traction. 该公司报告收入为10.1 EPS和123.3亿美元,估计亏损,净利润率为33.03%,股本回报率为68.91%。 The company reported $1.01 EPS and $12.43 billion in revenue, beating estimates, with a 33.03% net margin and 68.91% return on equity. 尽管该股票交易低于关键移动平均线,并且由于竞争和2026年预测疲软,与2024年高点相比下降66%,但其股价仍低估,P/E为13.97和股息收益率为3.7%. Though trading below key moving averages and down 66% from 2024 highs due to competition and weak 2026 guidance, the stock remains undervalued with a P/E of 13.97 and a 3.7% dividend yield. 该公司新的口服糖尿病药丸正在驱动需求,并正在扩大对非专利药的防守。 The firm’s new oral diabetes pill is driving demand, and it is expanding its defense against generics.